This article is available to subscribers. Subscribe now. Already have an account? Sign in

EditorialFree Preview

T-Cell Immunotherapy against Mutant KRAS for Pancreatic Cancer

List of authors.
  • Cornelis J.M. Melief, M.D., Ph.D.

Pancreatic ductal adenocarcinoma is the deadliest of all common cancers. The reasons for this are the advanced cancer stage by the time symptoms are noted and the occult presence of micrometastases in the liver and elsewhere at the time of initial surgical treatment. In addition, systemic therapy with chemotherapy rarely cures systemic disease, and immunotherapy with T-cell checkpoint inhibitors is notoriously ineffective. Therefore, the study reported by Leidner et al.1 in this issue of the Journal is remarkable because it shows deep and durable tumor shrinkage in a heavily pretreated patient who received an infusion of autologous T cells transduced . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.

Author Affiliations

From the Leiden University Medical Center, Leiden, and ISA Pharmaceuticals, Oegstgeest — both in the Netherlands.